NYSE:AIM

Aim Immunotech Stock News

Healthcare > Biotechnology

Buy AIM

*Your capital is at risk

$0.732

-0.0947 (-11.46%)

At Close: Jun 03, 2026

AIM CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc.

07:25am, Monday, 16'th Aug 2021

BioFlorida is the State's Leading Life Sciences Industry Association BioFlorida is the State's Leading Life Sciences Industry Association

AIM ImmunoTech inks contract to sponsor Phase 2a trial to test Ampligen as a cold and flu therapy

09:09am, Friday, 09'th Jul 2021

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company's Ampligen drug as a potential intranasal antiviral ther

8 ‘Must Watch' Penny Stocks For Your July 2021 List

09:03am, Friday, 09'th Jul 2021

Are these 'must watch' penny stocks on your radar? The post 8 ‘Must Watch' Penny Stocks For Your July 2021 List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

07:25am, Friday, 09'th Jul 2021

Subjects will be exposed under controlled clinical facilities and medical monitoring to A/Perth/16/2009 (H3N2) or human rhinovirus (hRV-16) to gauge Ampligen's effectiveness against those, and potenti

AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET

02:15pm, Tuesday, 06'th Jul 2021

OCALA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2

AIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen

09:00am, Monday, 21'st Jun 2021

Company is Planning a Phase 2 Study of its Drug as a Broad-Spectrum Respiratory Virus Prophylaxis Company is Planning a Phase 2 Study of its Drug as a Broad-Spectrum Respiratory Virus Prophylaxis

AIM ImmunoTech says Ampligen featured in medical journal as potential treatment for cancer patients infected with SARS-CoV-2

08:44am, Monday, 14'th Jun 2021

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) reports that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancer

AIM ImmunoTech's Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2

07:15am, Monday, 14'th Jun 2021

The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for Use in Combination with Checkpoint Blockade Inhibitors The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for

AIM ImmunoTech extends pact with Shenzhen Smoore Technology to develop Ampligen as inhalation therapy for coronavirus, other respiratory diseases

09:58am, Thursday, 27'th May 2021

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) has entered into a two-year agreement extension with Shenzhen Smoore Technology Limited (Smoore) with the goal of developing Ampligen as a potential i

AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen

08:45am, Thursday, 27'th May 2021

Announces plans to conduct Phase 1/2 clinical study incorporating new inhalation technology if the preliminary results of the testing are positive Announces plans to conduct Phase 1/2 clinical study i

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by